Table 6.
Medication adherence and persistence outcomes from included studies
| Author, year | Population | Treatment | Sample size (N) |
Timepoint (months) | Adherence | Persistence | ||
|---|---|---|---|---|---|---|---|---|
| Measure | Results | Measure | Results | |||||
| Busse, 2022 [14] | Patients with moderate/severe asthma | SITT: FF/UMEC/VI 100/62.5/25 mcg | 1396 | 3 | Proportion of days covered | Mean (SD) [median]: 0.68 (0.27) [0.67] | ||
| 6 | Mean (SD) [median]: 0.56 (0.31) [0.58] | |||||||
| 12 | Mean (SD) [median]: 0.46 (0.33) [0.41] | |||||||
| NR | Persistence duration |
Median: 131 days 12 months: aHR 1.49 (95% CI 1.36, 1.60) [reference: MITT] |
||||||
| MITT: FF/UMEC/VI 100/62.5/25 mcg | 5115 | 3 | Proportion of days covered | Mean (SD) [median]: 0.59 (0.30) [0.60] | ||||
| 6 | Mean SD [median]: 0.46 (0.31) [0.37] | |||||||
| 12 | Mean (SD) [median]: 0.35 (0.30) [0.25] | |||||||
| NR | Persistence duration | Median: 66 days | ||||||
| Oppenheimer, 2022 [16] | Patients with asthma | MITT: FF/UMEC/VI 100/62.5/25 mcg | 1831 | 12 | Proportion of days covered | Mean (SD): 0.31 (0.27) | Persistence | 12% |
| Spain, 2022 [17] | Patients with moderate/severe asthma | MITT: LAMA + ICS + LABA | 277,373 | 3 | Probability of discontinuation (LAMA) | 40.5% | ||
aHR adjusted hazard ratio, CI confidence interval, FF fluticasone furoate, ICS inhaled corticosteroid, LABA long-acting β2-agonist, LAMA long-acting muscarinic antagonist; MITT multiple-inhaler triple therapy, NR not reported, SD standard deviation, SITT single-inhaler triple therapy, UMEC umeclidinium, VI vilanterol